Liver cell circuits and therapeutic discovery for advanced liver disease and cancer.
Fiche publication
Date publication
novembre 2021
Journal
Comptes rendus biologies
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr CROUCHET Emilie
Tous les auteurs :
Crouchet E, Schuster C, Baumert TF
Lien Pubmed
Résumé
Hepatocellular carcinoma (HCC) is a major global health challenge with rising incidence. Despite the previous approval of several novel therapeutic approaches, HCC remains the second common cause of cancer-related death worldwide. The vast majority of HCCs arises in the context of chronic fibrotic liver diseases caused by viral or metabolic etiologies. In patients with advanced liver disease the risk of HCC persists even after viral cure or control of infection. Moreover, given the change in the lifestyle and increase of obesity and metabolic disorders, HCC incidence is predicted to drastically augment in the next decade. Early detection, improvement of the screening method in patient at-risk and development of chemopreventive strategies are therefore urgently needed to reduce HCC risk. This review summarizes the major challenges in the identification of patient at risk for HCC and the emergent strategies for HCC prevention to improve patients' outcome.
Mots clés
Chemoprevention, Epigenetic, Fibrosis, Gene signature, Hepatocellular carcinoma, Risk prediction
Référence
C R Biol. 2021 11 15;344(3):233-248